3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
53
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Neoplasms
3
Inflammatory Breast Neoplasms
3
HER2-positive Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Solid Tumor
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Colonic Neoplasms
2
Urinary Bladder Neoplasms
1
Solid Cancers
1
Patient Preference
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Multiple Endocrine Neoplasia
1
Malignant Solid Neoplasm
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
Her2-Positive Breast Cancer
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-Positive Early Breast Cancer
1
HER2 Positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
Cisplatin
32
human papillomavirus vaccine, L1 type 16, 18
16
Brachytherapy
15
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
12
Paclitaxel
11
Bevacizumab
11
pembrolizumab
10
Platinum
9
1,2-diaminocyclohexaneplatinum II citrate
9
Topotecan
8
Radiotherapy, Intensity-Modulated
8
Radiation
8
Papillomavirus Vaccines
8
atezolizumab
6
Gemcitabine
6
Fluorodeoxyglucose F18
6
Cyclophosphamide
6
tisotumab vedotin
5
fludarabine phosphate
5
fludarabine
5
aldesleukin
5
Taxes
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Carboplatin
5
Vaccines, Synthetic
4
Nivolumab
4
Immunoglobulin G
4
Disulfides
4
Colposcopy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Uterine Cervical Neoplasms
×
pertuzumab
×
Clear all
No trials found.